FDA Cites Imaging Drug Web Sites, Draws "Respectful" Disagreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Bracco Diagnostics took down a promotional Web site in response to an untitled letter from DDMAC but disagrees that it hyped a study. GE Healthcare's Visipaque is cited in a separate letter.
You may also be interested in...
Dr. Reddy’s Gets U.S. FDA Advertising Letter, But Its Response Is Far From Generic
Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.
Dr. Reddy’s Gets FDA Advertising Letter, But Its Response Is Far From Generic
Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.
Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person
In a series of letters, FDA cites Lilly, Cephalon, Bayer and Amylin for promotional violations.